Articles
20.02.2015
Is this the future for expensive drugs

Recent initiatives indicate EU member states are heading for potential centralised drug procurement

Read more
News
19.02.2015
Should the UK have a cost per QALY threshold

Should the UK have a cost per QALY threshold

Read more
07.01.2015
NICE revises biosimilar guidance

NICE revises biosimilars guidance to conclude that they do not believe that biosimilars are identica...

Read more
Articles
21.11.2014
Presentation to EUCOPE members by Remap Consulting

Remap Consulting presents NICE's highly specialised technology methodology to EUCOPE

Read more
News
02.10.2014
Incl. latest news on NICE's Value Based Assessment

Updates on the latest news on NICE's Value Based Assessment, as well as the approval of ultra-orphan...

Read more
Articles
23.07.2014
New tax proposed to manage healthcare expenditure

If spending on Hepatitis C drugs exceeds a certain amount, drug manufacturers will be taxed

Read more
News
07.07.2014
Incl. Is 2015 a turning point for bio similar

Including Sovaldi's $84,000 price, adaptive licence pilots from the EMA and is 2015 a turning point ...

Read more
News
20.05.2014
The latest in pharma pricing and market access

Our quarterly newsletter shares our perspectives on the latest news, developments and thinking withi...

Read more
Articles
15.05.2014
Impact of value and price on market access

How different perspectives on value and price can impact market access

Read more
Articles
13.05.2014
New Hepatitis drug cost

Attack on Sovaldi's controversial $84000 price tag by lawmakers

Read more
Older
Newer

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch